CMV423

Uses your system voice; voice and rate in settings.

Q15410869Snapshot

≈ 1 min read

Names in other languages

  • EnglishCMV423
  • shCMV423
  • СрпскиCMV423

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection and human herpesvirus 6 (HHV-6) infection. The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.

CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection and human herpesvirus 6 (HHV-6) infection. The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1148432242 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.